Journal of Gastroenterology

, Volume 46, Issue 11, pp 1335–1343

Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case–control study

  • Naoki Hiramatsu
  • Yuko Inoue
  • Tsugiko Oze
  • Nao Kurashige
  • Takayuki Yakushijin
  • Kiyoshi Mochizuki
  • Takuya Miyagi
  • Tomohide Tatsumi
  • Shinichi Kiso
  • Tatsuya Kanto
  • Akinori Kasahara
  • Tetsuo Takehara
  • Masahide Oshita
  • Eiji Mita
  • Hideki Hagiwara
  • Yoshiaki Inui
  • Kazuhiro Katayama
  • Shinji Tamura
  • Harumasa Yoshihara
  • Yasuharu Imai
  • Norio Hayashi
Original Article—Liver, Pancreas, and Biliary Tract

DOI: 10.1007/s00535-011-0455-1

Cite this article as:
Hiramatsu, N., Inoue, Y., Oze, T. et al. J Gastroenterol (2011) 46: 1335. doi:10.1007/s00535-011-0455-1

Abstract

Background

The antiviral effect of pegylated interferon (Peg-IFN) plus ribavirin combination therapy in chronic hepatitis C (CHC) patients with normal alanine aminotransferase (ALT) levels (N-ALT) has been reported to be equivalent to that for patients with elevated ALT levels (E-ALT). However, the actual antiviral effect in N-ALT patients remains obscure because efficacy can be overestimated in patients with an advantageous background.

Methods

In this study, 386 patients were extracted, for a matched case–control study, from 1320 CHC patients treated with Peg-IFN alpha-2b plus ribavirin combination therapy; 193 N-ALT patients [116 with hepatitis C virus genotype 1 (HCV-1), 77 with HCV genotype 2 (HCV-2)] were matched with 193 E-ALT patients by a propensity score method using the variables of age, sex, IFN treatment history, body mass index, and platelet counts.

Results

On multivariate analysis for sustained virological response (SVR) in N-ALT patients, younger age, low HCV RNA level at baseline, and HCV-2 were significant factors. The matched case–control study showed that the SVR rates of N-ALT patients were equivalent to those of E-ALT patients; at 49 and 40% in the HCV-1 group (P = 0.146), and 78 and 81% in the HCV-2 group (P = 0.691). However, in N-ALT patients with non-SVR, approximately 40% showed ALT elevation at 24 weeks post-treatment.

Conclusion

Our findings indicate that the antiviral effect of Peg-IFN plus ribavirin therapy in N-ALT patients is comparable to that for E-ALT patients irrespective of their advantageous background; however, the application of this therapy for N-ALT patients, especially for those with HCV-1, should be considered carefully.

Keywords

Hepatitis C virusNormal alanine aminotransferasePegylated interferon plus ribavirin combination therapyPropensity score methodMatched case–control study

Copyright information

© Springer 2011

Authors and Affiliations

  • Naoki Hiramatsu
    • 1
  • Yuko Inoue
    • 1
  • Tsugiko Oze
    • 1
  • Nao Kurashige
    • 1
  • Takayuki Yakushijin
    • 1
  • Kiyoshi Mochizuki
    • 1
  • Takuya Miyagi
    • 1
  • Tomohide Tatsumi
    • 1
  • Shinichi Kiso
    • 1
  • Tatsuya Kanto
    • 1
  • Akinori Kasahara
    • 1
  • Tetsuo Takehara
    • 1
  • Masahide Oshita
    • 2
  • Eiji Mita
    • 3
  • Hideki Hagiwara
    • 4
  • Yoshiaki Inui
    • 5
  • Kazuhiro Katayama
    • 6
  • Shinji Tamura
    • 7
  • Harumasa Yoshihara
    • 8
  • Yasuharu Imai
    • 9
  • Norio Hayashi
    • 4
  1. 1.Department of Gastroenterology and HepatologyOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Osaka Police HospitalOsakaJapan
  3. 3.National Hospital Organization Osaka National HospitalOsakaJapan
  4. 4.Kansai Rosai HospitalAmagasakiJapan
  5. 5.Hyogo Prefectural Nishinomiya HospitalNishinomiyaJapan
  6. 6.Osaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan
  7. 7.Minoh City HospitalMinohJapan
  8. 8.Osaka Rosai HospitalSakaiJapan
  9. 9.Ikeda Municipal HospitalIkedaJapan